Lupin's Board of Directors will hold a meeting on November 8 to discuss the company's unaudited financial results for the September quarter (Q2), the pharmaceutical major informed the exchanges on today.
Shares of the company have been trending down by 23.10 or 1.98 percent today, at ₹1,144.90, against previous close of ₹1,168.
On October 23, Lupin said it has received approval from the United States Food and Drug Adminstration (US FDA) to market its generic Fluconazole tablets used in the treatment of fungal infections, the company told the exchanges.
The approval is for he abbreviated new drug application of Fluconazole tablets in strengths of 50 mg, 100 mg, 150 mg and 200 mg, Lupin said. They will be manufactured at the company's Pithampur unit.
These are the generic equivalents of Diflucan tablets, 50 mg, 100 mg, 150 mg, and 200 mg, of Pfizer Inc, it added.
This product will be manufactured at Lupin's Pithampur facility in India, the company said. Fluconazole Tablets had estimated annual sales of $43 million in the US, Lupin said citing IQVIA MAT July 2023 data.
